Evidence map›Paper›PMID 38689322›Full record

ArticleEuropean journal of medical research2024

Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.

Wei Zhang, Xiao-Song Chen, Ying Wei, Xiao-Min Wang, Xian-Jin Chen, Bang-Teng Chi, Lin-Qing Huang, Rong-Quan He, Zhi-Guang Huang, Qi Li and 3 more

Erratum issuedAbstract read
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Homeobox C6 plays an oncogenic role in bladder cancer.World journal of clinical oncology · 2025
    Article
  2. Article
  3. Exploring the potential function of high expression ofWorld journal of gastrointestinal oncology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Wei Zhang *Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Xiao-Song Chen *Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Ying WeiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Xiao-Min WangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Xian-Jin ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Bang-Teng ChiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Lin-Qing HuangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Rong-Quan HeDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Zhi-Guang HuangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Qi LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Juan HeDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. hejuan@stu.gxmu.edu.cn.
Mei WuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. wm50@163.com.

Funding

Guangxi Educational Science Planning Key Project 2022ZJY2791Guangxi Higher Education Undergraduate Teaching Reform Project 2022JGA146Guangxi Medical University Undergraduate Education and Teaching Reform Project 2023Z10Guangxi Zhuang Autonomous Region Health Commission Scientific Research Project Z-A20230519
6 · The paper itself

Abstract

backgroundThis study aimed to explore the expression, molecular mechanism and its biological function of potassium two pore domain channel subfamily K member 1 (KCNK1) in bladder cancer (BC).

methodsWe integrated large numbers of external samples (n = 1486) to assess KCNK1 mRNA expression levels and collected in-house samples (n = 245) for immunohistochemistry (IHC) experiments to validate at the KCNK1 protein level. Single-cell RNA sequencing (scRNA-seq) analysis was performed to further assess KCNK1 expression and cellular communication. The transcriptional regulatory mechanisms of KCNK1 expression were explored by ChIP-seq, ATAC-seq and ChIA-PET data. Highly expressed co-expressed genes (HECEGs) of KCNK1 were used to explore potential signalling pathways. Furthermore, the immunoassay, clinical significance and molecular docking of KCNK1 were calculated.

resultsKCNK1 mRNA was significantly overexpressed in BC (SMD = 0.58, 95% CI [0.05; 1.11]), validated at the protein level (p < 0.0001). Upregulated KCNK1 mRNA exhibited highly distinguishing ability between BC and control samples (AUC = 0.82 [0.78-0.85]). Further, scRNA-seq analysis revealed that KCNK1 expression was predominantly clustered in BC epithelial cells and tended to increase with cellular differentiation. BC epithelial cells were involved in cellular communication mainly through the MK signalling pathway. Secondly, the KCNK1 transcription start site (TSS) showed promoter-enhancer interactions in three-dimensional space, while being transcriptionally regulated by GRHL2 and FOXA1. Most of the KCNK1 HECEGs were enriched in cell cycle-related signalling pathways. KCNK1 was mainly involved in cellular metabolism-related pathways and regulated cell membrane potassium channel activity. KCNK1 expression was associated with the level of infiltration of various immune cells. Immunotherapy and chemotherapy (docetaxel, paclitaxel and vinblastine) were more effective in BC patients in the high KCNK1 expression group. KCNK1 expression correlated with age, pathology grade and pathologic_M in BC patients.

conclusionsKCNK1 was significantly overexpressed in BC. A complex and sophisticated three-dimensional spatial transcriptional regulatory network existed in the KCNK1 TSS and promoted the upregulated of KCNK1 expression. The high expression of KCNK1 might be involved in the cell cycle, cellular metabolism, and tumour microenvironment through the regulation of potassium channels, and ultimately contributed to the deterioration of BC.

Indexed as

Gene Expression Regulation, NeoplasticPotassium Channels, Tandem Pore DomainUrinary Bladder NeoplasmsBiomarkers, TumorHumansMolecular Docking SimulationSignal TransductionBiomarkers, TumorKCNK1 protein, humanPotassium Channels, Tandem Pore DomainBiological functionsGene expressionKCNK1Molecular mechanismPotassium channel

Identifiers

PMID38689322
PMCPMC11059691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.